The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | Future of targeted therapies for non-colorectal GI cancers
Teresa Macarulla, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses promising targeted therapies for non-colorectal gastrointestinal cancers, including HER2-targeted therapies for biliary tract cancers, IDH1 and FGFR2 inhibitors for cholangiocarcinoma, PARP inhibitors for pancreatic cancer, and claudin18.2 and FGFR inhibitors for gastric cancer. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employment: Vall d´Hebrón University Hospital
Consultant or Advisory Role: Amgen, Serviere, Incyte, Sanofi, AstraZeneca, Taiho, Celgene
Research Funding: Celgen, AstraZeneca, BeiGene, Incyte
Speaking: AstraZeneca, Incyte, Serviere, Roche
